Endometrioma Clinical Trial
Official title:
Endometrioma Treatment and Ovarian Function
Ovarian endometriosis (endometrioma) can be a cause of subfertility. According to European
Society of Human Reproduction and Embryology (ESHRE) guidelines, surgery for endometrioma is
recommended when an endometrioma is more than 3 cm in diameter because this management is
associated with better spontaneous conception rates. Nevertheless, surgery can also be
potentially associated with a risk of destruction of functional ovarian tissue and reduction
in ovarian reserve.
Anti-müllerian hormone (AMH) is a member of the Transforming Growth Factor beta family and is
expressed by the small (<8 mm) pre-antral and early antral follicles. The AMH level reflects
the size of the primordial follicle pool, and may be the best biochemical marker of ovarian
function across an array of clinical situations Its level in serum is almost stable between
20 and 35 years of the woman´s life, unless using hormonal contraception and / or they suffer
with Polycystic ovarian syndrome (PCOS). The level of AMH is also a useful indicator for the
prediction chances of success of spontaneous or assisted conceptions. However, there paucity
of data regarding changes in serum levels of AMH following surgery for endometrioma.
An alternative way for estimating ovarian reserve is quantifying ovarian mass with using
standard 3D transvaginal ultrasound calculation (OVM) and assessment of antral follicular
count.
The gold standard of endometrioma surgery is laparoscopic excision with suture or gentle
coagulation of the rest of ovary or by the use of laparoscopic treatment with argon plasma
energy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01268930 -
Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas
|
N/A | |
| Completed |
NCT05323539 -
Comparison of Thyroid Volumes in Patients With and Without Endometrioma
|
N/A | |
| Recruiting |
NCT04178876 -
Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS)
|
N/A | |
| Recruiting |
NCT04151433 -
Conservative Endometrioma Surgery
|
N/A | |
| Completed |
NCT01942122 -
DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT00999479 -
Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation
|
N/A | |
| Recruiting |
NCT03687398 -
Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls
|
||
| Not yet recruiting |
NCT06377553 -
PET/MRI for Evaluation of Endometriosis
|
||
| Not yet recruiting |
NCT03788720 -
Suture of the Ovary After Enucleation of Ovarian Endometrioma
|
N/A | |
| Completed |
NCT01982526 -
Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients
|
||
| Recruiting |
NCT05962775 -
Ethanol Sclerotherapy Prior to ART
|
N/A | |
| Completed |
NCT03484546 -
Optimum Menstrual Cycle Time for Endometrioma Excision
|
||
| Completed |
NCT01808170 -
Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve
|
N/A | |
| Recruiting |
NCT05637073 -
Effect of Management of the Endometrioma on Ovarian Reserve
|
||
| Completed |
NCT06219044 -
Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization
|
N/A | |
| Recruiting |
NCT03620838 -
Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)
|
||
| Terminated |
NCT03571776 -
Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial
|
N/A | |
| Enrolling by invitation |
NCT02472873 -
Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
|
N/A | |
| Completed |
NCT04941833 -
Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo
|
Phase 2/Phase 3 | |
| Completed |
NCT06274086 -
Two-session Catheter-directed Sclerotherapy Using Ethanol for Endometrioma
|
N/A |